In recent years, tyrosine kinase inhibitors (EGFR-TKIs) have been used in NSCLC patients.8 Gefitinib, an EGFR-TKI, is used to treat advanced NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.